Cardiology Trials

Cardiology Trials

Health EN ↓ 149 episodes

An exploration of pivotal clinical trials in cardiovascular medicine that have significantly influenced the field. This podcast aligns with our publications on the Cardiology Trial's Substack. cardiologytrials.substack.com

Be sure to visit the podcast's website and support the creator: cardiologytrials.substack.com

Author

Cardiology Trials

Category

Health

Latest episode

Oct 21, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Review of the SYNTAX trial 22.10.2024

N Engl J Med 2009;360:961-972 Background: After its introduction in 1968, the use of coronary artery bypass grafting (CABG) in patients with coronary artery disease grew rapidly. Although early trial results were mixed (see the Veterans Administration Cooperative study , the European Coronary Surgery Study and the CASS study ), advancements in surgical techniques and the use of arterial conduits i...

Review of the ORBITA-2 trial 11.10.2024

N Engl J Med 2023;389:2319-2330 Background: Percutaneous coronary intervention (PCI) does not reduce mortality or myocardial infarction as seen in COURAGE , FAME 2 , ISCHEMIA and ISCHEMIA-CKD . However, unblinded studies have indicated that revascularization may improve symptoms, which is a key factor in driving PCI decisions for many patients. ORBITA was the first blinded, placebo-controlled tria...

Summary and discussion of ISCHEMIA, ISCHEMIA-CKD, ORBITA and REVIVED-BCIS2 04.10.2024

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the REVIVED-BCIS2 trial 01.10.2024

N Engl J Med 2022;387:1351-1360 Background: Systolic heart failure and obstructive coronary artery disease often coexist. Some patients show improvement in left ventricular systolic function after revascularization, which led to the development of the concept of myocardial hibernation. In this state, areas of the heart that are exposed to repetitive ischemia reduce their contractility to help faci...

Review of the ORBITA trial 26.09.2024

The Lancet Volume 391, Issue 10115, 6–12 January 2018, Pages 31-40 Background:   For decades, cardiologists commonly used percutaneous coronary intervention (PCI) for the relief of angina. It made sense because PCI resulted in near complete resolution of blood flow through a stenosed vessel. The problem facing evidence-based clinicians was that no previous trial had compared PCI to a placebo (sham...

Review of the ISCHEMIA and ISCHEMIA-CKD trials 23.09.2024

N Engl J Med 2020;382:1395-407 - ISCHEMIA N Engl J Med 2020;382:1608-16 - ISCHEMIA-CKD Background: The COURAGE trial , published in 2007, represented a major reversal in cardiovascular medicine. In patients with stable CAD an initial strategy of revascularization plus medical therapy did not reduce the chance of dying or having a heart attack compared to an initial strategy of medical therapy alon...

Summary and discussion of RITA-2, atorvastatin vs angioplasty, COURAGE and FAME 2 17.09.2024

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the FAME 2 Trial 12.09.2024

N Engl J Med 2012;367:991-1001 Background: Percutaneous coronary intervention (PCI) did not improve the outcome of death or nonfatal myocardial infarction in stable coronary artery disease, as seen in the COURAGE trial. Nonetheless, some skepticism remained within the cardiology community regarding the results of the COURAGE trial, with the belief that revascularizing ischemia-causing lesions coul...

Review of the COURAGE Trial 10.09.2024

N Engl J Med 2007;356:1503-1516 Background: By the turn of the 21st century more than 1 million coronary stent procedures were performed each year in the United States and approximately 85% were undertaken electively in patients with stable coronary artery disease. This pattern evolved without a single clinical trial demonstrating a concrete improvement in hard endpoints with percutaneous coronary...

Review of the Atorvastatin versus Revascularization Treatment Investigators Trial 05.09.2024

N Engl J Med 1999;341:70-76 Background: Percutaneous transluminal coronary angioplasty (PTCA) was widely used in the 1990s for its potential benefit in improving symptoms in patients with stable coronary artery disease, as discussed in the ACME and RITA-2 trials. However, the RITA-2 trial showed that PTCA worsened hard outcomes, and ACME was underpowered for such comparison. At the same time, tria...

Review of the RITA-2 trial 27.08.2024

Lancet 1997;350(9076):461-468 Background: In the ACME trial, percutaneous transluminal coronary angioplasty (PTCA) improved symptoms in patients with single-vessel stable coronary artery disease, but it did not lead to reduction in myocardial infarction or mortality, which were not primary endpoints and the study was under powered for these endpoints. The available data on the efficacy of PTCA for...

Summary and discussion of STICH and ACME 22.08.2024

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the ACME trial 20.08.2024

N Engl J Med 1992;326:10-16 Background: Revascularization with coronary artery bypass surgery improves symptoms in patients with chronic stable angina as seen in the European Coronary Surgery Study. Percutaneous transluminal coronary angioplasty (PTCA) is less invasive compared to surgery and is associated with less mortality and morbidity. Consequently, its use increased significantly in the late...

Review of the STICH trial 15.08.2024

N Engl J Med 2011;364:1607-1616 Background: The three pivotal trials of coronary artery bypass graft surgery (CABG) we previously reviewed, largely included patients with normal left ventricular function. Observational studies suggested that CABG improved survival over medical therapy in patients with coronary artery disease and systolic heart failure. Cardiology Trial’s Substack is a reader-suppo...

Summary and discussion of trials of coronary artery bypass surgery in stable angina 13.08.2024

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the Coronary Artery Bypass Graft Surgery Trialists Collaboration 09.08.2024

Lancet 1994;344(8922):563-570 Background: Several randomized trials have assessed the benefits of coronary artery bypass graft surgery (CABG) in patients with chronic stable angina. We reviewed three major trials in this area: The Veterans Administration Cooperative Study, the European Coronary Surgery Study , and the CASS study . These trials yielded divergent results, likely due to differences i...

Review of the Coronary Artery Surgery Study (CASS) 06.08.2024

Circulation 68, No. 5, 939-950, 1983 Background   Coronary artery bypass surgery (CABG) had grown in popularity through the 1970s and 1980s. By 1981, approximately 159,000 bypass surgeries had been done. Cardiology Trial’s Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. The goal of the CASS trial was to rigorously...

Review of the European Coronary Surgery Study 01.08.2024

Lancet 1982;320:1173-1180 Background: The first coronary artery bypass graft surgery (CABG) was performed in 1964 and by the 1970’s it was commonly used for relief of angina. However, whether it improved survival was unknown. The European Coronary Surgery Study (ECSS) sought to test the hypothesis that CABG compared to medical therapy improved survival at 5 years. Cardiology Trial’s Substack is a...

Review of the Veterans Administration Cooperative Study 30.07.2024

Circulation 1976; 54:Suppl:III-107-III-117 N Engl J Med 1977;297:621-627 Cardiology Trial’s Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Background: By the 1970's, coronary artery bypass surgery was performed to improve the quality of life in patients with chronic stable coronary artery disease. The Veterans Adm...

A review of medical management after acute coronary syndrome 12.07.2024

Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Summary and discussion of REDUCE-AMI 05.07.2024

For full review of the trial, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the REDUCE-AMI trial 02.07.2024

N Engl J Med 2024;390:1372-1381 Background: Beta-blockers are prescribed to the majority of patients with acute myocardial infarction. The bulk of evidence supporting this practice comes from trials published in the 1980s - BHAT and ISIS-I . Since the publication of these seminal trials, the care of patients with acute myocardial infarction has significantly changed with improvement in antiplatele...

Summary and discussion of PARADISE-MI and EMPACT-MI 28.06.2024

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial’s Substack at cardiologytrials.substack.com/subscribe

Review of the EMPACT-MI Trial 27.06.2024

N Engl J Med 2024;390:1455-1466 Background Despite advances in the care of patients after myocardial infarction, there remains residual risk of heart failure and death. The amount of risk parallels the degree of left ventricular systolic dysfunction. Previous studies have shown that the drug class of sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular risk (especially recurrent...

Review of the PARADISE-MI Trial 25.06.2024

NEJM 2021:385:1845-55. Background Over two decades had passed since the publications of the seminal trials comparing ACE inhibitors with placebo in post-MI patients with LV dysfunction and congestive heart failure (SAVE, AIRE and TRACE). The VALIANT trial, published in 2003, found that the ARB drug Valsartan was as effective as Captopril in improving survival and reducing cardiovascular morbidity...

Listen to the Cardiology Trials podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.